Tikun Olam-Cannbit Pharmaceuticals Ltd (TLV:TKUN)
Israel
· Delayed Price · Currency is ILS · Price in ILA 2,038.00
-159.00 (-7.24%)
Mar 9, 2026, 5:24 PM IDT
TLV:TKUN Revenue
In the year 2024, Tikun Olam-Cannbit Pharmaceuticals had annual revenue of 34.95M ILS, down -20.97%. Tikun Olam-Cannbit Pharmaceuticals had revenue of 14.10M in the half year ending December 31, 2024, a decrease of -49.90%.
Revenue
34.95M
Revenue Growth
-20.97%
P/S Ratio
0.50
Revenue / Employee
1.84M
Employees
19
Market Cap
17.32M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 34.95M | -9.28M | -20.97% |
| Dec 31, 2023 | 44.23M | -5.07M | -10.28% |
| Dec 31, 2022 | 49.30M | 12.27M | 33.13% |
| Dec 31, 2021 | 37.03M | 15.37M | 70.97% |
| Dec 31, 2020 | 21.66M | - | - |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Teva Pharmaceutical Industries | 55.02B |
| Danel (Adir Yeoshua) | 2.87B |
| Kamada | 578.74M |
| BrainsWay | 162.56M |
| Nextage Therapeutics | 413.00K |
| Bio-View | 17.88M |
| Evogene | 26.54M |
| Erika Carmel-Tech | 39.63M |